Results and discussion
CNrasGEF was isolated as part of our search for proteins that bind to the WW domains of the ubiquitin protein ligase Nedd4 [1] . A 450 nucleotide murine fragment encoding two PY motifs (xPPxY in the single-letter amino acid code) was isolated that was 75% identical (95% similar) at the amino acid level to the hypothetical gene product of the human GenBank entry KIAA0313. We renamed KIAA0313 to CNrasGEF, as it probably represents a novel class of Ras GEFs. CNrasGEF is related to the budding yeast protein Cdc25p and has several candidate domains, including, in amino to carboxyl order: cNMP-BD, REM, PDZ and RA domains, a Cdc25-related GEF domain, two PY motifs responsible for binding to the Nedd4 WW domain, and a carboxy-terminal SAV sequence conforming to PDZbinding motif consensus. The CNrasGEF Cdc25 domain is similar to the Ras GEF regions in Sos1/2, GRF1/2 and GRP, as well as in Rap GEFs such as Epac [2, 3] , but it contains a unique insertion (see Supplementary material) [4] . The PDZ domain of CNrasGEF appears most similar to those of Lin7, PTP-BAS, PSD-95 and Dlg (see Supplementary material). The cNMP-BD of CNrasGEF is similar to the cAMP-binding region of PKA and cAMP GEFs [2, 3] and to the cGMP-binding region of PKG and cyclicnucleotide-gated K + channels, although it lacks conservation of the AA or TA within the R(A/T)A motif found in PKA (and Epac) or in PKG, respectively (see Supplementary material). The arginine in the motif plays a key role in cyclic nucleotide binding, while the Ala and Thr play a role in conferring specificity for binding of cAMP or cGMP, respectively [5] . CNrasGEF mRNA is expressed predominantly in the brain, with widespread distribution (Figure 1b) . Accordingly, the ~180 kDa CNrasGEF protein is detected in the brain, including embryonic and adult rat brain synaptosomes, but not in several fibroblasts cell lines or HEK-293T cells (Figure 1c) .
We tested the ability of CNrasGEF to bind cAMP directly. Figure 2a shows that cAMP immobilized on agarose beads could bind soluble glutathione-S-transferase (GST)-cNMP-BD of CNrasGEF in vitro, suggesting direct interactions. Immobilized cAMP also precipitated full-length CNrasGEF from HEK-293T cells expressing CNrasGEF, but not from cells expressing CNrasGEF in which the cNMP-BD was deleted (∆cNMP-BD; Figure 2b ). Binding of cAMP to the CNrasGEF cNMP-BD was also effectively competed by cGMP (data not shown), suggesting that cGMP can also bind to the CNras-GEF cNMP-BD. This is consistent with lack of conservation within the RAA and RTA sequences in the cNMP-BD described above. The corresponding sequence in human or Drosophila CNrasGEF is (K/R)GV (see Supplementary material and Figure 2b ). Mutating the lysine to aspartate in the human KGV motif of the CNrasGEF cNMP-BD (K211D) abolished binding to cAMP (Figure 2b) , whereas an arginine to aspartate mutation in a RTK sequence just downstream of the KGV motif (R215D) had no effect (data not shown). This suggests that Lys211 is required for cAMP binding to CNrasGEF, equivalent to the role the arginine of the RAA motif plays in cAMP binding to PKA [5] .
As CNrasGEF contains a CDC25 domain homologous to those of GEF/GRFs for the Ras and Rap families of small GTPases, we tested the ability of CNrasGEF to activate Ras in response to cAMP or cGMP. We expressed FLAGtagged CNrasGEF in HEK-293T cells and tested its ability to activate Ras or Rap1 by a previously described method [6] [7] [8] . We used the following activation-specific probes for these GTPases: the Ras-binding domain (RBD) of Raf-1, which specifically binds the active, GTP-bound form of Ras, and the Rap1-binding domain of Ral-GDS, which binds the GTP-bound form of Rap1. Expression of CNrasGEF led to a weak activation of endogenous Ras, which was greatly enhanced by stimulation of cells with the membrane-permeable, nonhydrolyzable analogue of cAMP, 8-Br-cAMP ( Figure 3a ). This effect was independent of PKA activity, because cAMP was still able to stimulate CNrasGEF-mediated activation of Ras in the presence of H-89 or Rp-8-Br-cAMPS, two known inhibitors of PKA ( Figure 3a) . Similarly, 8-Br-cGMP, the membrane-permeable, non-hydrolyzable analogue of cGMP, was able to greatly enhance activation of Ras by CNrasGEF, and this effect was also independent of PKG activity, as determined by lack of effect of H-8 or Rp-8-BrcGMPS, two known inhibitors of PKG (Figure 3b ). Moreover, the activation of Ras by CNrasGEF in cells was also seen following treatment which leads to elevation of intracellular cAMP and cGMP concentrations: forskolin plus IBMX, or 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) plus DiPyridamole (DiPy), to elevate intracellular levels of cAMP or cGMP, respectively (Figure 3c ). Thus, these results suggest that both cAMP and cGMP can stimulate CNrasGEF to activate Ras in living cells.
To verify that this activation is mediated by the CDC25 domain and is dependent on the cNMP-BD of CNras-GEF, we performed similar experiments using CNras-GEF lacking its CDC25 domain (∆CDC25) or its cNMP-BD (∆cNMP-BD). As seen in Figure 3d , the 8-BrcAMP-mediated activation of Ras via wild-type CNras-GEF was almost abolished in the ∆CDC25 or ∆cNMP-BD mutants, demonstrating that both domains are required for the activation of Ras by CNrasGEF in cells. In vitro, we were unable to demonstrate significant activation of Ras by the isolated CDC25 domain of CNrasGEF (data not shown), but immunoprecipitated full-length CNrasGEF (which includes also the REM domain located far upstream of the CDC25 domain; see Figure 1a ) was able to moderately enhance Ras activation (Figure 3e) , with 2.9-fold activation in 30 minutes; this stimulation was lost in the ∆CDC25 mutant (Figure 3e) , and was not further enhanced by in vitro added 8-Br-cAMP (data not shown), suggesting different mechanism(s) of activation than that reported for Epac [3] . CNrasGEF-mediated activation of Ras in vitro was smaller than the 4.4-fold activation conferred by GRF2, used as a control (Figure 3e ). Unlike CNrasGEF, activation of GRF2 in cells was independent of cAMP (Figure 3f) , as expected. These results suggest that in its native conformation in cells, CNrasGEF becomes strongly active in response to elevated cAMP/cGMP levels, probably by direct nucleotide binding, although an indirect effect can not be ruled out. Ohtsuka et al. [9] recently identified the Rap1 GEF activity of CNrasGEF, which they termed nRap GEP. In agreement with their findings, we found that CNrasGEF can mediate activation of Rap1 in cells via its CDC25 domain, independent of cAMP stimulation (Figure 3g ).
Ras is localized at the plasma membrane and activation of Sos, GRF1/2 and GRP often involves their translocation from the cytosol to the plasma membrane [10] [11] [12] [13] . Immunostaining of CNrasGEF transfected into HEK-293T cells revealed that it is located at the periphery of the cell, suggesting that it is targeted to the plasma membrane (see Supplementary material). This localization was impaired in CNrasGEF lacking the PLPF (GLGF equivalent) sequence but not in cells expressing CNrasGEF bearing mutations in the PDZ-binding motif (SAV changed to AAA; see Supplementary material). Thus, the PDZ domain may be involved in targeting or tethering CNrasGEF to a PDZ-binding protein associated with the plasma membrane.
Ras and Rap1 have distinct subcellular localizations and interact with an overlapping set of effector proteins [14] . We conclude that CNrasGEF can activate both Rap1 and Ras, but only the activation of Ras, not of Rap1, is stimulated by binding of cAMP or cGMP; thus, elevation of intracellular cAMP or cGMP levels can cause a switch from Rap1 to Ras activation by CNrasGEF. In view of its strong expression in brain and synaptosomes, its activation by cyclic nucleotides, and the presence of a PDZ domain, we anticipate that either a plasma membrane protein such as a G-protein-coupled receptor that causes elevation of cAMP upon activation, or an ion channel enriched in synaptosomes (several of which possess a PDZ-binding motif) could be a candidate activator of CNrasGEF. The presence of CNrasGEF near or even in complex with such proteins could lead to a direct connection between them and Ras/Rap1 activation. CNrasGEF was identified in this study as a Nedd4-interacting protein, and our recent work has detected Nedd4 at the plasma membrane and in endosomes (P. Plant, F. LaFont, K. Simons and D.R., unpublished observations). This could provide a mechanism to regulate CNrasGEF interactions with Ras at the plasma membrane and Rap1 in endosomes. Finally, the association with Nedd4 may allow regulation of stability of CNrasGEF (or associated proteins) by ubiquitination.
Supplementary material
Supplementary material including CNrasGEF cellular localization, sequence alignments of various domains of CNrasGEF with related proteins and additional methodological details is available at http://current-biology.com/supmat/supmatin.htm.
